-+ 0.00%
-+ 0.00%
-+ 0.00%

Elanco Animal Health Gets Approval For Befrena From U.S. Department of Agriculture To Treat Canine Allergic And Atopic Dermatitis

Benzinga·12/31/2025 19:02:19
Listen to the news

Elanco Animal Health Incorporated (NYSE:ELAN) today announced its latest entry into the rapidly growing canine dermatology space with the U.S. Department of Agriculture (USDA) approval of Befrena™ (tirnovetmab), a new anti-IL31 monoclonal antibody (mAb) injection targeting canine allergic and atopic dermatitis. Importantly, Befrena is recommended at a dosing interval of 6 to 8 weeks post-treatment, which stands in contrast to the 4 to 8 weeks of the current market competitor, lokivetmab.

USDA approval of Befrena further demonstrates Elanco's commitment to going beyond to deliver differentiated, high-quality products in every key therapeutic area, specifically bolstering its leadership in canine dermatology and monoclonal antibodies. Elanco continues to expect to launch Befrena in the first half of 2026.